in 1943 yamanouchi yakuhin shokai was started in 1923 by kenji yamanouchi in osaka the company was renamed yamanouchi pharmaceutical co in 1940 and moved to tokyo in 1942 both companies started their overseas expansion at about the same time opening offices in taiwan in 1962 and 1963 respectively and in the united states and europe from 1977 onwards fujisawa acquired lyphomed in 1990 and thereafter established its us r d center in deerfield illinois yamanouchi s r d center in leiderdorp was established with the acquisition of the pharmaceutical division of royal gist brocades in 1991 fujisawa and yamanouchi combined in a merger of equals forming astellas pharma on 1 april 2005 at least some of its older products continue to be distributed under the original brand ostensibly due to high brand name recognition astellas had a collaboration agreement with comentis from 2008 to 2014 focused on development of beta secretase inhibitor therapeutics for alzheimer s disease in 2009 the company s tacrolimus containing products prograf and advagraf showed they were prone to dosing errors within europe leading to serious adverse reactions among a number of patients due to deficits in packaging and labeling deficits corrected after a warning